NE Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
["Not a good buy right now for an impatient investor: earnings are in a few days (Feb 11 AH), and recent fundamentals/insider activity skew risk to the downside near-term.", "Technicals remain broadly bullish (moving averages stacked bullish), but today\u2019s sharp drop and a contracting MACD suggest momentum is slowing and the stock may chop around support before a clean push higher.", "Options positioning is bullish-leaning (low put/call ratios), but that optimism conflicts with heavy insider selling and mixed analyst stance\u2014so risk/reward is not compelling at $37.1 ahead of the print."]
["Trend: Bullish structure with SMA_5 > SMA_20 > SMA_200 (uptrend intact).", "Momentum: MACD histogram is positive (0.32) but contracting, signaling fading upside momentum.", "RSI (6): 64.8 (neutral-to-warm), not overbought but leaning extended after the recent run.", "Price levels: Pivot 36.09 is the key near-term line; holding above it keeps the uptrend healthy.", "Support/Resistance: S1 34.16 (next downside level if 36 breaks); R1 38.02 then R2 39.21 (overhead supply).", "Context: Today\u2019s -3.46% drop vs S&P -1.17% = relative weakness on the day, suggesting buyers are not in full control right now."]
["Rig contracting/backlog: Recent contract awards and commentary (e.g., $1.3B backlog cited by Barclays) support medium-term revenue visibility.", "Analyst support on the bullish side: BTIG reiterated Buy and raised PT to $42; Barclays stays Overweight with PT $36 (near current).", "Pattern-based projection: Model indicates a favorable probability of gains over 1 week (+2.59%) and 1 month (+7.34%), if support holds."]
["Earnings event risk: Q4/FY25 results on 2026-02-11 after hours\u2014high probability of a volatility spike; not ideal for an impatient entry at current levels.", "Insider selling: Insiders are selling and selling amount increased ~9566.67% over the last month (clear negative signal).", "Fundamental deterioration in the latest reported quarter: margins and earnings turned meaningfully worse (see financials).", "Analyst disagreement: SEB downgraded to Sell with $33 PT, and JPMorgan moved to Neutral\u2014adds downside narrative near-term.", "No supportive \u201csmart money\u201d tailwind: Hedge funds flagged as Neutral with no significant trend last quarter.", "No political/congress tailwind: No recent congress trading data available; no noted influential-figure buying catalyst in provided data."]
["Latest quarter provided: 2025/Q3.", "Revenue: $757.4M, down -0.80% YoY (flat-to-down top line).", "Profitability: Net income -$21.1M (down -134.46% YoY) and EPS -0.13 (down -132.50% YoY) \u2014 moved deeper into losses.", "Margins: Gross margin 17.2%, down -40.15% YoY \u2014 significant margin compression trend."]
["Recent trend: Mixed\u2014some firms raised targets on contract/backlog optimism (BTIG to $42 Buy; Barclays to $36 Overweight), while others turned more cautious/downgraded (SEB to Sell $33; JPMorgan to Neutral $33; Citi Neutral with PT cut to $32).", "Wall Street pros: Backlog/contracting visibility improving and may de-risk 2026; offshore tone has improved with new signings.", "Wall Street cons: Sector cautiousness tied to upstream spending headwinds and crude uncertainty; dayrates viewed as sideways; multiple majors at Neutral/Downside targets close to or below current price ($32\u2013$33)."]
